Dear readers of ADxS.org, please forgive the disruption.

ADxS.org needs about $36850 in 2023. In 2022 we received donations from third parties of about $ 13870. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2023 would be over after a few days. This donation request is displayed 18,000 times a week, but only 40 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$16307 of $36850 - as of 2023-08-31
44%
I would like to donate via PayPal
More info about donations
ADxS.org Logo
ADxS.org Logo
Search Sitemap Donations Last Changes Deutsche Version
Register

Existing Account? Login

Header Image
Venlafaxine for ADHD

Sitemap

The ADxS.org project
Abstract of ADxS.org
Symptoms
Consequences
Origin
Stress
Neurological aspects
Diagnostics
Prevention
Treatment and therapy
Medication for ADHD - Overview
Suitable medication for ADHD
Experimental drugs for ADHD
Sleep disorder-related medications for ADHD
Appetite stimulating drugs for ADHD
ADHD drugs in development
Less appropriate medication for ADHD
Vitamins, minerals, dietary supplements for ADHD
Plant extracts for ADHD
Medication and drugs - the difference
Substance abuse with self-medication effects in ADHD.
This and That about ADHD
Tests and surveys
Forum

Venlafaxine for ADHD

Previous Page Next Page

Brand names of venlafaxine include: Trevilor (D), Efexor (CH), Efectin (A)

Venaflaxin came on the market in 1993 and is approved only for adults (18 years and older).1

Venlafaxine acts primarily at the serotonin level, secondarily at the norepinephrine level as a reuptake inhibitor (SSNRI = selective serotonin-norepinephrine reuptake inhibitor), and even less so at the dopamine level.1

Venlafaxine has only been tested in a few studies with a small number of subjects in relation to ADHD. The improvement in ADHD symptoms was very modest, while side effects were significant.2
We therefore advise against the use of venlafaxine in ADHD.

ATTENTION:
Regarding the entire group of serotonin reuptake inhibitors, there are concerns about their use in ADHD.
See ⇒ Comments on serotonin reuptake inhibitors (SSRIs) in ADHD In the article ⇒ Medications for ADHD - overview.

  1. Müller, Candrian, Kropotov (2011), ADHS – Neurodiagnostik in der Praxis, Springer, Seite 22 ↥ ↥

  2. Häßler (2009): substanzgebundene Alternativen in der Therapie von ADHS, Seite 175 f, in: Häßler (Hrsg) das ADHS Kaleidoskop – State of the Art und bisher nicht beachtete Aspekte von hoher Relevanz; medizinisch wissenschaftliche Verlagsgesellschaft ↥

Diese Seite wurde am 13.03.2023 zuletzt aktualisiert.
Previous Page Next Page